vs
Eastern Bankshares, Inc.（EBC）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Eastern Bankshares, Inc.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.4倍（$295.9M vs $207.3M），Eastern Bankshares, Inc.净利率更高（22.1% vs -62.0%，领先84.1%），Eastern Bankshares, Inc.同比增速更快（710.6% vs 25.9%），过去两年Eastern Bankshares, Inc.的营收复合增速更高（38.6% vs 38.0%）
东方银行股份有限公司总部位于美国马萨诸塞州波士顿，2020年完成股份化改制前，是美国历史最悠久、规模最大的互助银行，同时也是马萨诸塞州规模最大的社区银行，深耕本地金融服务，在区域零售及小微金融领域拥有深厚的运营积淀。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
EBC vs RARE — 直观对比
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $295.9M | $207.3M |
| 净利润 | $65.3M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | — | -54.7% |
| 净利率 | 22.1% | -62.0% |
| 营收同比 | 710.6% | 25.9% |
| 净利润同比 | -34.4% | 3.5% |
| 每股收益（稀释后） | $0.29 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | $295.9M | — | ||
| Q4 25 | $37.5M | $207.3M | ||
| Q3 25 | $241.5M | $159.9M | ||
| Q2 25 | $244.9M | $166.5M | ||
| Q1 25 | $31.1M | $139.3M | ||
| Q4 24 | $216.5M | $164.6M | ||
| Q3 24 | $203.4M | $139.5M | ||
| Q2 24 | $154.0M | $147.0M |
| Q1 26 | $65.3M | — | ||
| Q4 25 | $99.5M | $-128.6M | ||
| Q3 25 | $106.1M | $-180.4M | ||
| Q2 25 | $100.2M | $-115.0M | ||
| Q1 25 | $-217.7M | $-151.1M | ||
| Q4 24 | $60.8M | $-133.2M | ||
| Q3 24 | $-6.2M | $-133.5M | ||
| Q2 24 | $26.3M | $-131.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | -54.7% | ||
| Q3 25 | 38.9% | -106.9% | ||
| Q2 25 | 41.0% | -64.8% | ||
| Q1 25 | -590.9% | -102.6% | ||
| Q4 24 | 33.3% | -74.3% | ||
| Q3 24 | -1.6% | -94.6% | ||
| Q2 24 | 24.7% | -79.1% |
| Q1 26 | 22.1% | — | ||
| Q4 25 | 265.6% | -62.0% | ||
| Q3 25 | 44.0% | -112.8% | ||
| Q2 25 | 40.9% | -69.0% | ||
| Q1 25 | -699.2% | -108.5% | ||
| Q4 24 | 28.1% | -80.9% | ||
| Q3 24 | -3.0% | -95.7% | ||
| Q2 24 | 17.1% | -89.5% |
| Q1 26 | $0.29 | — | ||
| Q4 25 | $0.48 | $-1.28 | ||
| Q3 25 | $0.53 | $-1.81 | ||
| Q2 25 | $0.50 | $-1.17 | ||
| Q1 25 | $-1.08 | $-1.57 | ||
| Q4 24 | $0.29 | $-1.34 | ||
| Q3 24 | $-0.03 | $-1.40 | ||
| Q2 24 | $0.16 | $-1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $551.7M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.3B | $-80.0M |
| 总资产 | $30.6B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q1 26 | $551.7M | — | ||
| Q4 25 | $507.6M | $421.0M | ||
| Q3 25 | $703.4M | $202.5M | ||
| Q2 25 | $948.3M | $176.3M | ||
| Q1 25 | $609.0M | $127.1M | ||
| Q4 24 | $1.9B | $174.0M | ||
| Q3 24 | $1.7B | $150.6M | ||
| Q2 24 | $1.4B | $480.7M |
| Q1 26 | $4.3B | — | ||
| Q4 25 | $4.3B | $-80.0M | ||
| Q3 25 | $3.8B | $9.2M | ||
| Q2 25 | $3.7B | $151.3M | ||
| Q1 25 | $3.6B | $144.2M | ||
| Q4 24 | $3.6B | $255.0M | ||
| Q3 24 | $3.7B | $346.8M | ||
| Q2 24 | $3.0B | $432.4M |
| Q1 26 | $30.6B | — | ||
| Q4 25 | $30.6B | $1.5B | ||
| Q3 25 | $25.5B | $1.2B | ||
| Q2 25 | $25.5B | $1.3B | ||
| Q1 25 | $25.0B | $1.3B | ||
| Q4 24 | $25.6B | $1.5B | ||
| Q3 24 | $25.5B | $1.5B | ||
| Q2 24 | $21.0B | $1.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
| Q1 26 | — | — | ||
| Q4 25 | $432.4M | $-99.8M | ||
| Q3 25 | $157.1M | $-91.4M | ||
| Q2 25 | $123.9M | $-108.3M | ||
| Q1 25 | $47.3M | $-166.5M | ||
| Q4 24 | $283.8M | $-79.3M | ||
| Q3 24 | $108.3M | $-67.0M | ||
| Q2 24 | $54.3M | $-77.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-100.8M | ||
| Q3 25 | — | $-92.7M | ||
| Q2 25 | — | $-110.7M | ||
| Q1 25 | — | $-167.8M | ||
| Q4 24 | — | $-79.5M | ||
| Q3 24 | — | $-68.6M | ||
| Q2 24 | — | $-79.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | -48.6% | ||
| Q3 25 | — | -58.0% | ||
| Q2 25 | — | -66.5% | ||
| Q1 25 | — | -120.5% | ||
| Q4 24 | — | -48.3% | ||
| Q3 24 | — | -49.2% | ||
| Q2 24 | — | -53.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 1.4% |
| Q1 26 | — | — | ||
| Q4 25 | 4.35× | — | ||
| Q3 25 | 1.48× | — | ||
| Q2 25 | 1.24× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 4.67× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.06× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EBC
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
